本文已被：浏览 5697次 下载 0次
中文摘要: 目的 探讨老年直肠癌晚期患者行XELOX和贝伐单抗治疗后腹腔镜辅助根治术的临床疗效。方法 回顾性研究老年患者66例，手术方式均为腹腔镜辅助根治直肠癌切除术。随机将患者分为治疗组（33例）和对照组（33例）。治疗组在术前行XELOX和贝伐单抗（bevacizumab，Bev）治疗（Bev 7.5 mg/kg + XELOX方案），而对照组在术前行常规化疗XELOX方案。比较两组术中术后基本情况、术后不良反应和并发症、术后复发率、术后生存期以及术后生存质量。结果 两组患者术中术后基本情况比较差异不显著，因此术后不同化疗方案治疗疗效具有可比性。两组患者术后出现并发症的差异不显著，但术后不良反应中，治疗组患者的便秘以及出血不良发生率明显高于对照组。两组患者术后1年复发率无显著差异，但治疗组的2年、3年和5年复发率均显著低于对照组。两组患者治疗组的术后2年、3年和5年生存期均高于对照组，且有显著差异。结论 在老年直肠癌患者中行XELOX联合贝伐单抗治疗后腹腔镜辅助根治术，能有效控制肿瘤复发，增加老年患者的2年无病生存期，提高老年患者生存质量，对老年直肠癌患者具有重要临床意义。
中文关键词: 腹腔镜辅助 直肠癌切除术 XELOX联合贝伐单抗 疗效
Abstract:Objective To investigate the clinical efficacy of laparoscopic-assisted radical resection after XELOX combined with bevacizumab treatment in elderly patients with advanced rectal cancer. Methods A review study of 66 elderly patients in general surgery from performed by laparoscopy assisted radical rectorectal excision . The patients were randomly divided into treatment group (33 cases) and control group (33 cases). The treatment group received preoperative XELOX and bevacizumab (Bev) treatment (Bev 7.5 mg/kg + XELOX regimen), while the control group received preoperative routine chemotherapy XELOX regimen. The basic conditions were compared between the two groups, then postoperative adverse reactions and complications, postoperative recurrence rate, postoperative survival time and postoperative quality of life were also compared between two groups. Results There was no significant difference between the two groups. in the basic situation of operation and postoperative, so the curative effect of different chemotherapy regimens after surgery is credible. There was no significant difference in postoperative complications between the two groups , but the incidence of constipation and hemorrhage in treatment patients was significantly higher than that of the control group patients . There was no significant difference in the 1 year recurrence rate between the two groups , but the 2 year recurrence rate, 3 year recurrence rate and 5 year recurrence rate were significantly lower than that of the control group in the treatment group . The 2-year disease-free survival, 3-year survival and 5-year survival of the treatment group were significantly higher than those of the control group . Finally, the survival time of the treatment group was significantly higher than that of the control group . Conclusion Laparoscopic-assisted radical resection after XELOX combined with bevacizumab treatment can effectively control the recurrence of the tumor, increase the 2-year disease-free survival and improve the quality of life of the elderly patients, which is of important clinical significance for the elderly patients with rectal cancer.
文章编号：3202007028 中图分类号：R735.3 文献标志码：
基金项目:
| Author Name | Affiliation |
引用文本：